Jump to content
RemedySpot.com

Re: LDN for Crohns

Rate this topic


Guest guest

Recommended Posts

Hi Dave,

I will forward on some earlier messages from the site regarding Cronhs.

Many people have had success with LDN, and there is a trial that appears to

be very promising.

Welcome to the group

Aletha

[low dose naltrexone] LDN for Crohns

> I'm new here. I am seeking input, both good and bad from people who

> have taken LDN for Crohns.

> Dave D

>

>

>

>

>

>

Link to comment
Share on other sites

That is very good that Dr. Zagon is part of the research team. Is there a reason why I should be surprised?

Kindest of regards

Aletha

[low dose naltrexone] LDN for Crohns> > > > I'm new here. I am seeking input, both good and bad from people who> > have taken LDN for Crohns.> > Dave D> >> >> >> >> >> >

Link to comment
Share on other sites

Hi Dave,

Here's some info for you ...

Regards,

Cris

1) Digestive Diseases Week Conference, Los Angeles - May 2006

- PRESENTATION ABSTRACT ID#S1397

- TITLE: Low-Dose Naltrexone as a Treatment For Active Crohn's

Disease

- AUTHORS: J. P. ; H. E. Stock; S. I. Bingaman; D. T. Mauger;

I. S. Zagon

- SESSION TITLE/SESSION TYPE: Clinical Intestinal Disorders:

Inflammat..., Poster Session

- PRESENTATION DATE/TIME: Sun, May 21, 8:00 AM

- LOCATION: West Hall A (LA Convention Center).

Low-Dose Naltrexone as a Treatment For Active Crohn's Disease

J. P. (1); H. E. Stock (1); S. I. Bingaman (1); D. T. Mauger

(2); I. S. Zagon (3)

1. Medicine, The Pennsylvania State University College of Medicine,

Hershey, PA, USA.

2. Health Evaluation Sciences, The Pennsylvania State University

College of Medicine, Hershey, PA, USA.

3. Neural and Behavioral Sciences, The Pennsylvania State University

College of Medicine, Hershey, PA, USA.

Background and Aims:

Endogenous opioids and opioid antagonists have been shown to play a

role in healing and repair of tissues. In an open-labeled pilot

prospective trial, the safety and efficacy of low-dose naltrexone

(LDN), an opioid antagonist given at a dosage that exacerbates opioid-

opioid receptor interactions, was tested in humans as a treatment for

active Crohn's disease.

Methods:

Eligible subjects with histologically and endoscopically confirmed

active Crohn's disease with a Crohn's Activity Index (CDAI) score of

220-450 were enrolled in a study using 4.5 mg naltrexone/day.

Subjects were required to be off infliximab for at least 8-weeks, and

this medication was not allowed during the trial. Other drug therapy

for Crohn's disease utilized 4 or more weeks prior to enrollment was

continued at the same dosages.

Patients completed the Inflammatory Bowel Disease Questionnaire

(IBDQ) and the Short-form (SF-36) quality of life (QOL) surveys

before treatment, every four weeks on therapy, and 4-weeks after

completion of the study drug. Drug was administered orally each

evening for a 12-week period. Laboratory tests, erythrocyte

sedimentation rates, C-Reactive protein, and CDAI scores were

assessed monthly and 4 weeks after discontinuing the medication.

Results:

Seventeen patients with a mean initial CDAI score of 356 ± 27 were

enrolled in the study. CDAI scores decreased significantly (p<0.01)

with LDN, and remained statistically lower than baseline 4-weeks

after completing therapy (see Figure). Eighty-nine percent of

patients exhibited a response to therapy (>70-point decrease in CDAI,

p<0.001) and 67% achieved remission (CDAI score <150). QOL surveys

indicated marked improvement with LDN. No laboratory abnormalities

were noted. One subject undergoing routine endoscopic procedures

showed healing of the intestinal mucosa. In both subjects with open

fistulas, closure was noted with LDN. The most common side effect of

LDN was sleep disturbances (7 patients).

Conclusions:

LDN therapy offers an alternative safe, effective, and economic means

of treating subjects with active Crohn's disease.

http://ddw2006.abstractcentral.com/planner

2) Digestive Diseases Week Conference, Los Angeles - May 2006

PRESENTATION ABSTRACT ID# T1155 - TITLE: The Opioid Antagonist

Naltrexone Alleviates Chemically-Induced Colitis- AUTHORS: G. L.

Matters, J. F. Harms, L. R. Fitzpatrick, A. M. Parikh, N. J. Nilo, J.

P. . SESSION TITLE/SESSION TYPE: Consequences of Intestinal

Inflammation, Poster Session - PRESENTATION DATE/TIME: Tue, May 23,

8:30 AM - LOCATION: West Hall A (LA Convention Center).

The Opioid Antagonist Naltrexone Alleviates Chemically-Induced Colitis

G. L. Matters (1); J. F. Harms (2); L. R. Fitzpatrick (3); A. M.

Parikh (2); N. J. Nilo(2); J. P. (2)

1. Biochemistry and Molecular Biology, The Pennsylvania State

University

College of Medicine, Hershey, PA, USA.

2. Medicine, The Pennsylvania State University College of Medicine,

Hershey,

PA, USA.

3. Surgery, The Pennsylvania State University College of Medicine,

Hershey,

PA, USA.

Background and Aims: Endogenous opioids have been shown to influence

inflammatory responses through the modulation of cytokine production.

Additionally, opioid antagonists promote tissue growth and repair. It

was

hypothesized that the opioid antagonist naltrexone could reduce

inflammation

and promote repair of the bowel in a chemically-induced mouse model of

inflammatory bowel disease.

Methods: Forty-eight C57BL/6J mice were divided into two groups: one

received untreated drinking water and the other received 2% dextran

sodium

sulfate (DSS) for 5 days. On the third day after DSS was introduced, 8

animals in each group were injected subcutaneously with 0.1 ml saline

(control) or naltrexone (NTX, 0.1 or 10 mg/kg) daily for 5 days.

Disease

activity index (DAI) scores, based on weight loss and stool

hemoccult, were

calculated daily. Mice were necropsied on day 9 and inflammation of

the

distal colons was analyzed histologically. Colonic RNA was evaluated

by

microarray and real-time RT-PCR.

Results: By day 4, DSS-treated animals had significant weight loss (p

=

0.006) and a higher DAI score (p < 0.001) compared to water controls.

At

necropsy, DSS-treated mice that received NTX (10 mg/kg) had less

weight loss

(30.8%), lower DAI scores (24.6%), and less inflammation (25.0%)

compared to

DSS mice that received only saline. Real-time RT-PCR demonstrated an

increased expression of the cytokines IL-6 and IL-12 in DSS-treated

mice.

The increase in these pro-inflammatory cytokines was reversed by NTX

treatment to levels near or equal to the expression in mice without

colitis.

Furthermore, the expression of the transcription factors STAT3 and

STAT4,

downstream effectors of cytokine signaling, was upregulated in the

colons of

DSS-treated mice and similarly reversed by NTX.

Conclusions: NTX treatment reverses the disease manifestations and

histologic evidence of inflammation in DSS-induced colitis. The

mechanism by

which NTX acts to reverse colitis is related in part to the decreased

expression of pro-inflammatory cytokines (IL-6 and IL-12) and their

downstream mediators (STAT3 and STAT4).

http://ddw2006.abstractcentral.com/planner#

> > [low dose naltrexone] LDN for Crohns

> >

> >

> > > I'm new here. I am seeking input, both good and bad from

people who

> > > have taken LDN for Crohns.

> > > Dave D

Link to comment
Share on other sites

dave if you go www.lowdosenaltrxone.org and you can go to the 2006

conference and you can listen to an entire audio of Dr Jill

who is doing really incredible work in the field of Cronhns with ldn.

cyndi

On Oct 23, 2006, at 10:47 PM, Aletha Wittmann wrote:

> Hi Dave,

>

> I will forward on some earlier messages from the site regarding

> Cronhs.

> Many people have had success with LDN, and there is a trial that

> appears to

> be very promising.

>

> Welcome to the group

> Aletha

> [low dose naltrexone] LDN for Crohns

>

>

>> I'm new here. I am seeking input, both good and bad from people who

>> have taken LDN for Crohns.

>> Dave D

>>

>>

>>

>>

>>

>>

Link to comment
Share on other sites

  • 2 weeks later...

What about Colitis Ulcerosa,

I don\t find that mentioned on the ldn info site..

Geir Flatabø

On 10/24/06, Cyndi Lenz <psychrn@...> wrote:

> dave if you go www.lowdosenaltrxone.org and you can go to the 2006

> conference and you can listen to an entire audio of Dr Jill

> who is doing really incredible work in the field of Cronhns with ldn.

> cyndi

> On Oct 23, 2006, at 10:47 PM, Aletha Wittmann wrote:

>

> > Hi Dave,

> >

> > I will forward on some earlier messages from the site regarding

> > Cronhs.

> > Many people have had success with LDN, and there is a trial that

> > appears to

> > be very promising.

> >

> > Welcome to the group

> > Aletha

> > [low dose naltrexone] LDN for Crohns

> >

> >

> >> I'm new here. I am seeking input, both good and bad from people who

> >> have taken LDN for Crohns.

> >> Dave D

> >>

> >>

> >>

> >>

> >>

> >>

Link to comment
Share on other sites

>

> What about Colitis

Ulcerosa,

> I don\t find that

mentioned on the ldn info

site..

>

> Geir Flatabø

>

=========

Go back to the LDN

website, ulcerative

colitis is listed next to

the bottom under other

diseasess. Look at the

list of diseases, one

side is cancers the other

side is other diseases

and ulcerative colitis is

on that list under other

diseases.

Link to comment
Share on other sites

Hi Geir,

I have a friend with UC. She has not yet started LDN as we are looking for

doctor for her to prescribe it. When we asked if anyone else has tried LDN

with UC, we found 2 people that said it has worked well.

You can also try coconut oil. You should start out with only 1 teaspoon a

day and slowly build yourself up to 2 to 4 tablespoons a day. My friend has

started that a week ago. You can cook with it, put it a smoothie, add in

your baking or even rub it on your skin.

My best

Aletha

[low dose naltrexone] LDN for Crohns

> >

> >

> >> I'm new here. I am seeking input, both good and bad from people who

> >> have taken LDN for Crohns.

> >> Dave D

> >>

> >>

> >>

> >>

> >>

> >>

Link to comment
Share on other sites

  • 1 month later...

Join the conversation

You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

Loading...
×
×
  • Create New...